Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Asset Resilience Ratio
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has an Asset Resilience Ratio of 11.06% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial agility of Shanghai Fudan-Zhangjiang Bio-Pharmaceut to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2022)
This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Shanghai Fudan-Zhangjiang Bio-Pharmaceut balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Shanghai Fudan-Zhangjiang Bio-Pharmaceut.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥280.00 Million | 11.06% |
| Total Liquid Assets | CN¥280.00 Million | 11.06% |
Asset Resilience Insights
- Moderate Liquidity: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd has 11.06% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2022)
The table below shows the annual Asset Resilience Ratio data for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 1.12% | CN¥33.32 Million ≈ $4.88 Million |
CN¥2.98 Billion ≈ $435.48 Million |
+1.12pp |
| 2011-12-31 | 0.00% | CN¥11.00K ≈ $1.61K |
CN¥358.88 Million ≈ $52.52 Million |
-0.04pp |
| 2010-12-31 | 0.05% | CN¥143.00K ≈ $20.93K |
CN¥304.15 Million ≈ $44.51 Million |
+0.02pp |
| 2006-12-31 | 0.03% | CN¥38.00K ≈ $5.56K |
CN¥145.02 Million ≈ $21.22 Million |
-0.31pp |
| 2005-12-31 | 0.33% | CN¥475.00K ≈ $69.51K |
CN¥142.91 Million ≈ $20.91 Million |
-- |
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more